Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
| 中文名称 | Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- |
|---|---|
| 中文同义词 | 化合物 T13379;化合物(Z)-LEUKADHERIN-1 |
| 英文名称 | Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- |
| 英文同义词 | Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-;ADH-503 free base;ADH503,orally,macrophages,repolarization,dendritic,ADH 503,Complement System,allosteric,ADH-503,CD11b,tumorassociated,(Z)Leukadherin1,Inhibitor,(Z) Leukadherin 1,tumor-infiltrating,inhibit,immunosuppressive |
| CAS号 | 2055362-72-4 |
| 分子式 | C22H15NO4S2 |
| 分子量 | 421.49 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 2055362-72-4.mol |
| 结构式 | ![Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- 结构式](CAS/20200401/GIF/2055362-72-4.gif) |
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- 性质
| 沸点 | 634.7±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.50±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.11±0.10(Predicted) |
| 颜色 | 浅黄至黄色 |
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- 用途与合成方法
CD11b
(Z)-Leukadherin-1 (ADH-503 free base; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b + cells and subsets of CD11b + monocytes, granulocytes, eosinophils, and macrophages.
(Z)-Leukadherin-1 (ADH-503 free base; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
(Z)-Leukadherin-1 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.
| Animal Model: | KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras G12D /p53 flox/flox ] |
| Dosage: | 30, 60, or 120 mg/kg |
| Administration: | Oral gavage; 60 days |
| Result: | Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. |
| Animal Model: | Male rats |
| Dosage: | 30, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral gavage twice a day; on days 1 and 5 |
| Result: | Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively. |